Why the study?
Are cytochrome P450 genetic variants and their interactions associated with clopidogrel resistance and adverse clinical outcomes in patients with acute ischemic stroke?
Population
375 consecutive patients with acute ischemic stroke (IS)
Comparison
Clopidogrel therapy with genotyping for eight… vs Patients without clopidogrel resistance or…
Design
Cohort
Follow-up
six months
Authors
Loading...
CYP2C19*2 and CYP3A5 variants were associated with resistance and outcomes in stroke; hypothesis-generating, warrants prospective trials before guiding therapy.
Are cytochrome P450 genetic variants and their interactions associated with clopidogrel resistance and adverse clinical outcomes in patients with acute ischemic stroke?
CYP2C19*2 and CYP3A5 genetic variants and their interactions independently predict clopidogrel resistance and adverse clinical outcomes in patients with acute ischemic stroke.
Yi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: